Methods and compositions for locally increasing body fat
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/425
C07D-277/34
A61K-031/4439
A61K-047/12
출원번호
US-0297671
(2014-06-06)
등록번호
US-8883834
(2014-11-11)
발명자
/ 주소
Kalayoglu, Murat V.
Singer, Michael S.
출원인 / 주소
Topokine Therapeutics, Inc.
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
4인용 특허 :
55
초록▼
Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a com
Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention.
대표청구항▼
1. A method for augmenting a body part in a subject in need thereof, the method comprising topically administering to the skin of the body part a composition comprising: oleic acid; and between about 0.1 percent and 2 percent by weight, inclusive, of a thiazolidinedione selected from the group consi
1. A method for augmenting a body part in a subject in need thereof, the method comprising topically administering to the skin of the body part a composition comprising: oleic acid; and between about 0.1 percent and 2 percent by weight, inclusive, of a thiazolidinedione selected from the group consisting of: and pharmaceutically acceptable salts thereof. 2. The method of claim 1, wherein the thiazolidinedione is rosiglitazone or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the thiazolidinedione is pioglitazone or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein the administering is about once a day. 5. The method of claim 1, wherein the concentration of the oleic acid in the composition is between about 1 and about 10 percent by weight, inclusive. 6. The method of claim 1, wherein the augmenting comprises selectively augmenting a portion of the body part. 7. The method of claim 1, wherein the method does not cause a clinically significant systemic effect. 8. The method of claim 2, wherein the method does not cause a clinically significant systemic effect. 9. The method of claim 3, wherein the method does not cause a clinically significant systemic effect. 10. The method of claim 4, wherein the method does not cause a clinically significant systemic effect. 11. The method of claim 5, wherein the method does not cause a clinically significant systemic effect. 12. The method of claim 6, wherein the method does not cause a clinically significant systemic effect. 13. The method of claim 1, wherein the body part is selected from the group consisting of the face, lips, breast, limbs, hands, trunk, hips, and buttocks. 14. The method of claim 1, wherein the body part is a hand. 15. The method of claim 1, wherein the body part is a cheek. 16. The method of claim 1, wherein the body part is a breast. 17. The method of claim 1, wherein the subject suffers from dissatisfaction with the size or contour of a body part. 18. The method of claim 13, wherein the method does not cause a clinically significant systemic effect. 19. The method of claim 1, wherein the subject suffers from a subcutaneous fat deficiency. 20. The method of claim 19, wherein the method does not cause a clinically significant systemic effect.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (55)
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tennenbaum, Tamar; Braiman-Wiksman, Liora; Solominik, Inessa; Meir, Michal, Method and compositions for prevention and treatment of diabetic and aged skin.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.